{"transactions":[{"id":4628952,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-02T21:54:32.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":322,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 322 shares of common stock (\"Common Stock\") of Incyte Corporation (the \"Issuer\") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the \"Stock Incentive Plan\") in lieu of quarterly director retainer fees of $40,500. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the \"Board\") as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Includes beneficial ownership of 15,505 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 14,722 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an \"RSU\"), 1,642 shares of Common Stock underlying unvested RSUs and 245,000 shares of Common Stock received previously from the exercise of 245,000 non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in\nsuch securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker\nmay be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisitions of RSUs reported on this form represent a single grant of 322 RSUs on Table I. The 322 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":28206082,"source":{"system":"sec-edgar","filing":"0001193125-26-412653","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1580575/000119312526412653/ownership.xml","form_type":"4"}},{"id":4628951,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-02T21:54:32.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":322,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 322 shares of common stock (\"Common Stock\") of Incyte Corporation (the \"Issuer\") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the \"Stock Incentive Plan\") in lieu of quarterly director retainer fees of $40,500. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the \"Board\") as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Includes beneficial ownership of 15,505 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 14,722 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an \"RSU\"), 1,642 shares of Common Stock underlying unvested RSUs and 245,000 shares of Common Stock received previously from the exercise of 245,000 non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in\nsuch securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker\nmay be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisitions of RSUs reported on this form represent a single grant of 322 RSUs on Table I. The 322 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":2835403,"source":{"system":"sec-edgar","filing":"0001193125-26-412653","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1580575/000119312526412653/ownership.xml","form_type":"4"}},{"id":4633321,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-29","kind":"purchase","planned":false,"acquired":true,"shares":1416,"price":85.8855,"value":121613.868,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.82 to $85.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":20191214,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633320,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-29","kind":"purchase","planned":false,"acquired":true,"shares":84,"price":85.8855,"value":7214.382,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.82 to $85.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1669727,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633319,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-29","kind":"purchase","planned":false,"acquired":true,"shares":20031,"price":85.403,"value":1710707.493,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.16 to $85.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":20189798,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633318,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-29","kind":"purchase","planned":false,"acquired":true,"shares":1195,"price":85.403,"value":102056.585,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.16 to $85.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1669643,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633317,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-29","kind":"purchase","planned":false,"acquired":true,"shares":10381,"price":84.2421,"value":874517.2401,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $83.81 to $84.65, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":20169767,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633316,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-29","kind":"purchase","planned":false,"acquired":true,"shares":619,"price":84.2421,"value":52145.8599,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $83.81 to $84.65, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1668448,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633315,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":196608,"price":89.8555,"value":17666310.144,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $89.11 to $90.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":20159386,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633314,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":11729,"price":89.8555,"value":1053915.1595,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $89.11 to $90.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1667829,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633313,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":82673,"price":89.6036,"value":7407798.4228,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $89.32 to $90.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19962778,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633312,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":4932,"price":89.6036,"value":441924.9552,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $89.32 to $90.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1656100,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633311,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":107772,"price":88.646,"value":9553556.712,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $88.01 to $89.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19880105,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633310,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":6428,"price":88.646,"value":569816.488,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $88.01 to $89.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1651168,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633309,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":98561,"price":88.5671,"value":8729261.9431,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $88.25 to $88.97, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19772333,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633308,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":5880,"price":88.5671,"value":520774.548,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $88.25 to $88.97, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1644740,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633307,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":75176,"price":87.5065,"value":6578388.644,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $87.03 to $88.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19673772,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633306,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":4485,"price":87.5065,"value":392466.6525,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $87.03 to $88.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1638860,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633305,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":63539,"price":86.9421,"value":5524214.0919,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $86.47 to $87.465, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19598596,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633304,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":3790,"price":86.9421,"value":329510.559,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $86.47 to $87.465, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1634375,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633303,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":16036,"price":86.8142,"value":1392152.5112,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $86.47 to $87.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19535057,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633302,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":957,"price":86.8142,"value":83081.1894,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $86.47 to $87.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1630585,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633301,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":3114,"price":86.7217,"value":270051.3738,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $86.70 to $86.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19519021,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633300,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":186,"price":86.7217,"value":16130.2362,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $86.70 to $86.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1629628,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633354,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":38932,"price":85.9656,"value":3346812.7392,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.50 to $86.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19515907,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633353,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":2322,"price":85.9656,"value":199612.1232,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.50 to $86.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1629442,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633352,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":109842,"price":84.8543,"value":9320566.0206,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $84.41 to $85.40, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19476975,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633351,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":6553,"price":84.8543,"value":556050.2279,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $84.41 to $85.40, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1627120,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633350,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":123888,"price":83.9512,"value":10400546.2656,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $83.39 to $84.39, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19367133,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633349,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":7390,"price":83.9512,"value":620399.368,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $83.39 to $84.39, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1620567,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633348,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":19554,"price":83.1552,"value":1626016.7808,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $82.66 to $83.38, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19243245,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633347,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1167,"price":83.1552,"value":97042.1184,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $82.66 to $83.38, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1613177,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633346,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1699,"price":82.6822,"value":140477.0578,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $82.52 to $82.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19223691,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633345,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":101,"price":82.6822,"value":8350.9022,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $82.52 to $82.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1612010,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633344,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":651,"price":81.915,"value":53326.665,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19221992,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633343,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":39,"price":81.915,"value":3194.685,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1611909,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633342,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":28028,"price":81.8162,"value":2293144.4536,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $81.27 to $82.22, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19221341,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633341,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1672,"price":81.8162,"value":136796.6864,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $81.27 to $82.22, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1611870,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633340,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":17490,"price":81.3139,"value":1422180.111,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $81.31 to $81.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19193313,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633339,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1044,"price":81.3139,"value":84891.7116,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $81.31 to $81.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1610198,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633338,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":5654,"price":81.2019,"value":459115.5426,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.935 to $81.73, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19175823,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633337,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":338,"price":81.2019,"value":27446.2422,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.935 to $81.73, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1609154,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633336,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":17159,"price":81.0204,"value":1390229.0436,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.455 to $81.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19170169,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633335,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1024,"price":81.0204,"value":82964.8896,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.455 to $81.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1608816,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633334,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1027,"price":80.52,"value":82694.04,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19153010,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633333,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":61,"price":80.52,"value":4911.72,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1607792,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633332,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":6783,"price":80.2259,"value":544172.2797,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.00 to $80.79, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19151983,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633331,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":404,"price":80.2259,"value":32411.2636,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.00 to $80.79, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1607731,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633330,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":14827,"price":79.7076,"value":1181824.5852,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $79.44 to $80.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19145200,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633329,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":884,"price":79.7076,"value":70461.5184,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $79.44 to $80.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1607327,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633328,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":283,"price":79.63,"value":22535.29,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19130373,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633327,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":17,"price":79.63,"value":1353.71,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1606443,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633326,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":8956,"price":79.4045,"value":711146.702,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $79.07 to $79.55, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19130090,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633325,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":534,"price":79.4045,"value":42402.003,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $79.07 to $79.55, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1606426,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633424,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":49771,"price":78.5681,"value":3910412.9051,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $77.92 to $78.91, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19121134,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633423,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":2969,"price":78.5681,"value":233268.6889,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $77.92 to $78.91, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1605892,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633422,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":48350,"price":77.4314,"value":3743808.19,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $76.94 to $77.88, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19071363,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633421,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":2884,"price":77.4314,"value":223312.1576,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $76.94 to $77.88, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1602923,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633420,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":61700,"price":76.345,"value":4710486.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $75.88 to $76.88, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19023013,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633419,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":3681,"price":76.345,"value":281025.945,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $75.88 to $76.88, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1600039,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633418,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":32261,"price":75.5151,"value":2436192.6411,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $74.88 to $75.86, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18961313,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633417,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1924,"price":75.5151,"value":145291.0524,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $74.88 to $75.86, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1596358,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633416,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":76723,"price":73.9686,"value":5675092.8978,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $73.88 to $74.86, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18929052,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633415,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":4577,"price":73.9686,"value":338554.2822,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $73.88 to $74.86, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1594434,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633414,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":78726,"price":73.0777,"value":5753115.0102,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $72.77 to $73.77, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18852329,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633413,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":4696,"price":73.0777,"value":343172.8792,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $72.77 to $73.77, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1589857,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633412,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":278978,"price":72.3873,"value":20194464.1794,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $71.77 to $72.765, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18773603,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633411,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":16641,"price":72.3873,"value":1204597.0593,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $71.77 to $72.765, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1585161,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633410,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":17698,"price":71.4843,"value":1265129.1414,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $70.80 to $71.76, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18494625,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633409,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1056,"price":71.4843,"value":75487.4208,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $70.80 to $71.76, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1568520,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633408,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":39066,"price":68.9578,"value":2693905.4148,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $68.65 to $69.52, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18476927,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633407,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":2331,"price":68.9578,"value":160740.6318,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $68.65 to $69.52, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1567464,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633406,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":2585,"price":68.3736,"value":176745.756,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $68.28 to $68.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18437861,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633405,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":154,"price":68.3736,"value":10529.5344,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $68.28 to $68.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1565133,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633404,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":5382,"price":67.0967,"value":361114.4394,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $66.86 to $67.23, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18435276,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633403,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":321,"price":67.0967,"value":21538.0407,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $66.86 to $67.23, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1564979,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633402,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":8021,"price":64.4276,"value":516773.7796,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $63.72 to $64.66, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18429894,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633401,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":479,"price":64.4276,"value":30860.8204,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $63.72 to $64.66, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1564658,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633400,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":4067,"price":62.9623,"value":256067.6741,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $62.48 to $63.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18421873,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633399,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":243,"price":62.9623,"value":15299.8389,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $62.48 to $63.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1564179,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633398,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":44690,"price":61.6252,"value":2754030.188,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $61.44 to $62.43, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18417806,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633397,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":2666,"price":61.6252,"value":164292.7832,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $61.44 to $62.43, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1563936,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633396,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":14344,"price":61.2104,"value":878001.9776,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $60.50 to $61.42, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18373116,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633395,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":856,"price":61.2104,"value":52396.1024,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $60.50 to $61.42, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1561270,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4623993,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Share Options","published_at":"2026-09-16T20:18:45.000Z","date":"2026-09-14","kind":"exercise","planned":false,"acquired":false,"shares":30768,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"The Share Options vested in 3 equal annual installments on April 19, 2018, April 19, 2019 and April 19, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"American Depositary Shares (\"ADS\") of BeOne Medicines Ltd. (the \"Issuer\") received upon exercise of 15,384 non-qualified share options to purchase ADS or Ordinary Shares (\"Share Options\") that were issued to each of Ranjeev Krishana and Michael Goller, full-time employees of Baker Bros. Advisors LP (the \"Adviser\") for their prior service as directors of the Issuer. Ranjeev Krishana and Michael Goller, pursuant to the policies of the Adviser, do not have any right to the pecuniary interest in the Share Options issued for their prior service on the board of directors of the Issuer (the \"Board\") or the ADS or Ordinary Shares received upon exercise of such Share Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons owns an indirect proportionate pecuniary interest in the ADS received upon exercise of the Share Options issued in connection with Ranjeev Krishana and Michael Goller's prior service on the Board less the exercise cost of those Share Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his current service on the Board and Ranjeev Krishana and Michael Goller do not have the right to any of the Issuer's securities issued as compensation for their past service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F18","text":"The ADS reported represent a total of 30,768 ADS received upon exercise of 15,384 Share Options issued to each of Ranjeev Krishana and Michael Goller. This amount is reported for each of the Funds as each has an indirect proportionate pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":36.83,"expiration_date":"2026-12-11","underlying":"American Depositary Shares","underlying_shares":30768},"source":{"system":"sec-edgar","filing":"0001193125-26-393103","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526393103/ownership.xml","form_type":"4"}},{"id":4623992,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Share Options","published_at":"2026-09-16T20:18:45.000Z","date":"2026-09-14","kind":"exercise","planned":false,"acquired":false,"shares":30768,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"The Share Options vested in 3 equal annual installments on April 19, 2018, April 19, 2019 and April 19, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"American Depositary Shares (\"ADS\") of BeOne Medicines Ltd. (the \"Issuer\") received upon exercise of 15,384 non-qualified share options to purchase ADS or Ordinary Shares (\"Share Options\") that were issued to each of Ranjeev Krishana and Michael Goller, full-time employees of Baker Bros. Advisors LP (the \"Adviser\") for their prior service as directors of the Issuer. Ranjeev Krishana and Michael Goller, pursuant to the policies of the Adviser, do not have any right to the pecuniary interest in the Share Options issued for their prior service on the board of directors of the Issuer (the \"Board\") or the ADS or Ordinary Shares received upon exercise of such Share Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons owns an indirect proportionate pecuniary interest in the ADS received upon exercise of the Share Options issued in connection with Ranjeev Krishana and Michael Goller's prior service on the Board less the exercise cost of those Share Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II directly held by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his current service on the Board and Ranjeev Krishana and Michael Goller do not have the right to any of the Issuer's securities issued as compensation for their past service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F18","text":"The ADS reported represent a total of 30,768 ADS received upon exercise of 15,384 Share Options issued to each of Ranjeev Krishana and Michael Goller. This amount is reported for each of the Funds as each has an indirect proportionate pecuniary interest in such securities."}],"balance_after":0,"derivative":{"exercise_price":36.83,"expiration_date":"2026-12-11","underlying":"American Depositary Shares","underlying_shares":30768},"source":{"system":"sec-edgar","filing":"0001193125-26-393103","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526393103/ownership.xml","form_type":"4"}},{"id":4623991,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares","published_at":"2026-09-16T20:18:45.000Z","date":"2026-09-14","kind":"exercise","planned":false,"acquired":true,"shares":30768,"price":36.83,"value":1133185.44,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F14","text":"Each ADS represents 13 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"American Depositary Shares (\"ADS\") of BeOne Medicines Ltd. (the \"Issuer\") received upon exercise of 15,384 non-qualified share options to purchase ADS or Ordinary Shares (\"Share Options\") that were issued to each of Ranjeev Krishana and Michael Goller, full-time employees of Baker Bros. Advisors LP (the \"Adviser\") for their prior service as directors of the Issuer. Ranjeev Krishana and Michael Goller, pursuant to the policies of the Adviser, do not have any right to the pecuniary interest in the Share Options issued for their prior service on the board of directors of the Issuer (the \"Board\") or the ADS or Ordinary Shares received upon exercise of such Share Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons owns an indirect proportionate pecuniary interest in the ADS received upon exercise of the Share Options issued in connection with Ranjeev Krishana and Michael Goller's prior service on the Board less the exercise cost of those Share Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his current service on the Board and Ranjeev Krishana and Michael Goller do not have the right to any of the Issuer's securities issued as compensation for their past service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares or ADS received upon vesting of restricted share units (each an \"RSU\"), Share Options, and Ordinary Shares or ADS received upon the exercise of Share Options, in each case that were received as a result of Felix J. Baker's current or Ranjeev Krishana's and Michael Goller's past service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares or ADS received upon vesting of RSUs, Share Options, and Ordinary Shares or ADS received upon the exercise of Share Options (i.e., no direct pecuniary interest)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares or ADS received as a result of the exercise of Share Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F18","text":"The ADS reported represent a total of 30,768 ADS received upon exercise of 15,384 Share Options issued to each of Ranjeev Krishana and Michael Goller. This amount is reported for each of the Funds as each has an indirect proportionate pecuniary interest in such securities."}],"balance_after":8099179,"source":{"system":"sec-edgar","filing":"0001193125-26-393103","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526393103/ownership.xml","form_type":"4"}},{"id":4623990,"issuer":{"id":2168,"kind":"organization","name":"BeOne Medicines Ltd.","symbol":"ONC"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares","published_at":"2026-09-16T20:18:45.000Z","date":"2026-09-14","kind":"exercise","planned":false,"acquired":true,"shares":30768,"price":36.83,"value":1133185.44,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F14","text":"Each ADS represents 13 Ordinary Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"American Depositary Shares (\"ADS\") of BeOne Medicines Ltd. (the \"Issuer\") received upon exercise of 15,384 non-qualified share options to purchase ADS or Ordinary Shares (\"Share Options\") that were issued to each of Ranjeev Krishana and Michael Goller, full-time employees of Baker Bros. Advisors LP (the \"Adviser\") for their prior service as directors of the Issuer. Ranjeev Krishana and Michael Goller, pursuant to the policies of the Adviser, do not have any right to the pecuniary interest in the Share Options issued for their prior service on the board of directors of the Issuer (the \"Board\") or the ADS or Ordinary Shares received upon exercise of such Share Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons owns an indirect proportionate pecuniary interest in the ADS received upon exercise of the Share Options issued in connection with Ranjeev Krishana and Michael Goller's prior service on the Board less the exercise cost of those Share Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 5 of Table I and in column 9 of Table II directly held by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his current service on the Board and Ranjeev Krishana and Michael Goller do not have the right to any of the Issuer's securities issued as compensation for their past service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Funds each own an indirect proportionate pecuniary interest in the Ordinary Shares or ADS received upon vesting of restricted share units (each an \"RSU\"), Share Options, and Ordinary Shares or ADS received upon the exercise of Share Options, in each case that were received as a result of Felix J. Baker's current or Ranjeev Krishana's and Michael Goller's past service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Ordinary Shares or ADS received upon vesting of RSUs, Share Options, and Ordinary Shares or ADS received upon the exercise of Share Options (i.e., no direct pecuniary interest)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Ordinary Shares or ADS received as a result of the exercise of Share Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F18","text":"The ADS reported represent a total of 30,768 ADS received upon exercise of 15,384 Share Options issued to each of Ranjeev Krishana and Michael Goller. This amount is reported for each of the Funds as each has an indirect proportionate pecuniary interest in such securities."}],"balance_after":761410,"source":{"system":"sec-edgar","filing":"0001193125-26-393103","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526393103/ownership.xml","form_type":"4"}},{"id":691282,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":3,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"2026 $0.0001 Prefunded Warrants","published_at":"2026-08-11T21:46:08.000Z","date":"2026-08-11","kind":"purchase","planned":false,"acquired":true,"shares":2609946,"price":12.0599,"value":31475687.7654,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") purchased 126,394 and 2,609,946 warrants to purchase common stock (\"Common Stock\") of Replimune Group, Inc. (the \"Issuer\") (\"2026 $0.0001 Prefunded Warrants\"), respectively, for $12.0599 per warrant pursuant to an underwritten public offering that closed on August 11, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The 2026 $0.0001 Prefunded Warrants have no expiration date and are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The 2026 $0.0001 Prefunded Warrants have no expiration date and are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") purchased 126,394 and 2,609,946 warrants to purchase common stock (\"Common Stock\") of Replimune Group, Inc. (the \"Issuer\") (\"2026 $0.0001 Prefunded Warrants\"), respectively, for $12.0599 per warrant pursuant to an underwritten public offering that closed on August 11, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The 2026 $0.0001 Prefunded Warrants have no expiration date and are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":2609946,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":2609946},"source":{"system":"sec-edgar","filing":"0001193125-26-345144","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526345144/ownership.xml","form_type":"4"}},{"id":691281,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":2,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":3,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"2026 $0.0001 Prefunded Warrants","published_at":"2026-08-11T21:46:08.000Z","date":"2026-08-11","kind":"purchase","planned":false,"acquired":true,"shares":126394,"price":12.0599,"value":1524299.0006,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") purchased 126,394 and 2,609,946 warrants to purchase common stock (\"Common Stock\") of Replimune Group, Inc. (the \"Issuer\") (\"2026 $0.0001 Prefunded Warrants\"), respectively, for $12.0599 per warrant pursuant to an underwritten public offering that closed on August 11, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The 2026 $0.0001 Prefunded Warrants have no expiration date and are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The 2026 $0.0001 Prefunded Warrants have no expiration date and are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") purchased 126,394 and 2,609,946 warrants to purchase common stock (\"Common Stock\") of Replimune Group, Inc. (the \"Issuer\") (\"2026 $0.0001 Prefunded Warrants\"), respectively, for $12.0599 per warrant pursuant to an underwritten public offering that closed on August 11, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The 2026 $0.0001 Prefunded Warrants have no expiration date and are exercisable at an exercise price of $0.0001 per share immediately at any time at the option of the holder on a 1-for-1 basis into Common Stock to the extent that after giving effect to such exercise the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 4.99% of the outstanding shares of Common Stock (the \"Maximum Percentage\") immediately prior to and following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":126394,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":126394},"source":{"system":"sec-edgar","filing":"0001193125-26-345144","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526345144/ownership.xml","form_type":"4"}},{"id":719143,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2026-07-02T20:32:36.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":17731,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 17,731 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") granted by the Issuer to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\"), on June 30, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Equity Incentive Plan. The Stock Options have a strike price of $38.96 per share, and vest on the earlier of the first anniversary of the grant date or one day prior to the date of the next annual meeting of stockholders of the Issuer, subject to Felix J. Baker's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 29, 2036."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 17,731 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") granted by the Issuer to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\"), on June 30, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Equity Incentive Plan. The Stock Options have a strike price of $38.96 per share, and vest on the earlier of the first anniversary of the grant date or one day prior to the date of the next annual meeting of stockholders of the Issuer, subject to Felix J. Baker's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 29, 2036."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Felix J. Baker serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Felix J. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Felix J. Baker of 17,731 Stock Options on Table II. This grant of 17,731 Stock Options for Felix J. Baker is reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":17731,"derivative":{"exercise_price":38.96,"expiration_date":"2036-06-29","underlying":"Common Stock","underlying_shares":17731},"source":{"system":"sec-edgar","filing":"0001193125-26-294724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526294724/ownership.xml","form_type":"4"}},{"id":719142,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2026-07-02T20:32:36.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":17731,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 17,731 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") granted by the Issuer to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\"), on June 30, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Equity Incentive Plan. The Stock Options have a strike price of $38.96 per share, and vest on the earlier of the first anniversary of the grant date or one day prior to the date of the next annual meeting of stockholders of the Issuer, subject to Felix J. Baker's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 29, 2036."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 17,731 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") granted by the Issuer to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\"), on June 30, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Equity Incentive Plan. The Stock Options have a strike price of $38.96 per share, and vest on the earlier of the first anniversary of the grant date or one day prior to the date of the next annual meeting of stockholders of the Issuer, subject to Felix J. Baker's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 29, 2036."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Felix J. Baker serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Felix J. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Felix J. Baker of 17,731 Stock Options on Table II. This grant of 17,731 Stock Options for Felix J. Baker is reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":17731,"derivative":{"exercise_price":38.96,"expiration_date":"2036-06-29","underlying":"Common Stock","underlying_shares":17731},"source":{"system":"sec-edgar","filing":"0001193125-26-294724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526294724/ownership.xml","form_type":"4"}},{"id":719803,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:31:15.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":400,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 400 shares of common stock (\"Common Stock\") of Incyte Corporation (the \"Issuer\") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the \"Stock Incentive Plan\") in lieu of quarterly director retainer fees of $40,500. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the \"Board\") as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Includes beneficial ownership of 15,105 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 14,722 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an \"RSU\"), 1,642 shares of Common Stock underlying unvested RSUs and 245,000 shares of Common Stock received previously from the exercise of 245,000 non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in\nsuch securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker\nmay be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisitions of RSUs reported on this form represent a single grant of 400 RSUs on Table I. The 400 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":28205760,"source":{"system":"sec-edgar","filing":"0001193125-26-294712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879169/000119312526294712/ownership.xml","form_type":"4"}},{"id":719802,"issuer":{"id":3182,"kind":"organization","name":"INCYTE CORP","symbol":"INCY"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:31:15.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":400,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 400 shares of common stock (\"Common Stock\") of Incyte Corporation (the \"Issuer\") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the \"Stock Incentive Plan\") in lieu of quarterly director retainer fees of $40,500. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the \"Board\") as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Includes beneficial ownership of 15,105 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 14,722 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an \"RSU\"), 1,642 shares of Common Stock underlying unvested RSUs and 245,000 shares of Common Stock received previously from the exercise of 245,000 non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in\nsuch securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker\nmay be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisitions of RSUs reported on this form represent a single grant of 400 RSUs on Table I. The 400 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":2835081,"source":{"system":"sec-edgar","filing":"0001193125-26-294712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879169/000119312526294712/ownership.xml","form_type":"4"}},{"id":724684,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-29T20:41:06.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 6,000 non-qualified stock options (\"Stock Options\") exercisable solely into Class A common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 26, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan. The Stock Options have a strike price of $35.08 per share and vest on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of the Issuer's shareholders, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 26, 2036."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 6,000 non-qualified stock options (\"Stock Options\") exercisable solely into Class A common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 26, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan. The Stock Options have a strike price of $35.08 per share and vest on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of the Issuer's shareholders, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 26, 2036."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Cheong serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Cheong does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Cheong of 6,000 Stock Options on Table II. This grant of 6,000 Stock Options for Dr. Cheong is reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":6000,"derivative":{"exercise_price":35.08,"expiration_date":"2036-06-26","underlying":"Class A common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001193125-26-288602","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526288602/ownership.xml","form_type":"4"}},{"id":724683,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-29T20:41:06.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 6,000 non-qualified stock options (\"Stock Options\") exercisable solely into Class A common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 26, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan. The Stock Options have a strike price of $35.08 per share and vest on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of the Issuer's shareholders, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 26, 2036."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 6,000 non-qualified stock options (\"Stock Options\") exercisable solely into Class A common stock (\"Common Stock\") of vTv Therapeutics Inc. (the \"Issuer\") granted by the Issuer to Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\"), on June 26, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2024 Equity Incentive Plan. The Stock Options have a strike price of $35.08 per share and vest on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of the Issuer's shareholders, subject to Dr. Cheong's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on June 26, 2036."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Dr. Cheong serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Dr. Cheong does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Dr. Cheong of 6,000 Stock Options on Table II. This grant of 6,000 Stock Options for Dr. Cheong is reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":6000,"derivative":{"exercise_price":35.08,"expiration_date":"2036-06-26","underlying":"Class A common stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001193125-26-288602","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526288602/ownership.xml","form_type":"4"}},{"id":726944,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-25T21:10:52.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":6068,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"6,068 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Kymera Therapeutics, Inc. (the \"Issuer\") were granted under the Issuer's 2020 Stock Option and Incentive Plan to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") in his capacity as a director of the Issuer. The Stock Options have a strike price of $99.87 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Felix J. Baker's continued service on the board of directors of the Issuer (the \"Board\") through such vesting date and expire on June 23, 2036. Felix J. Baker serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"6,068 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Kymera Therapeutics, Inc. (the \"Issuer\") were granted under the Issuer's 2020 Stock Option and Incentive Plan to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") in his capacity as a director of the Issuer. The Stock Options have a strike price of $99.87 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Felix J. Baker's continued service on the board of directors of the Issuer (the \"Board\") through such vesting date and expire on June 23, 2036. Felix J. Baker serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Pursuant to the policies of Baker Bros. Advisors LP (the \"Adviser\"), Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interests in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options and any Common Stock acquired upon the exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service. Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock acquired as a result of the exercise of the Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The acquisition of Stock Options reported on this form represents a single grant to Felix J. Baker of 6,068 Stock Options on Table II. This grant of 6,068 Stock Options to Felix J. Baker is reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":6068,"derivative":{"exercise_price":99.87,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":6068},"source":{"system":"sec-edgar","filing":"0001193125-26-283039","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526283039/ownership.xml","form_type":"4"}},{"id":726943,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-25T21:10:52.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":6068,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"6,068 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Kymera Therapeutics, Inc. (the \"Issuer\") were granted under the Issuer's 2020 Stock Option and Incentive Plan to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") in his capacity as a director of the Issuer. The Stock Options have a strike price of $99.87 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Felix J. Baker's continued service on the board of directors of the Issuer (the \"Board\") through such vesting date and expire on June 23, 2036. Felix J. Baker serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"6,068 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Kymera Therapeutics, Inc. (the \"Issuer\") were granted under the Issuer's 2020 Stock Option and Incentive Plan to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") in his capacity as a director of the Issuer. The Stock Options have a strike price of $99.87 per share, and vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders of the Issuer, subject to Felix J. Baker's continued service on the board of directors of the Issuer (the \"Board\") through such vesting date and expire on June 23, 2036. Felix J. Baker serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Pursuant to the policies of Baker Bros. Advisors LP (the \"Adviser\"), Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interests in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options and any Common Stock acquired upon the exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service. Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock acquired as a result of the exercise of the Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The acquisition of Stock Options reported on this form represents a single grant to Felix J. Baker of 6,068 Stock Options on Table II. This grant of 6,068 Stock Options to Felix J. Baker is reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":6068,"derivative":{"exercise_price":99.87,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":6068},"source":{"system":"sec-edgar","filing":"0001193125-26-283039","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526283039/ownership.xml","form_type":"4"}},{"id":732670,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2026-06-18T20:03:45.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":1532,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F10","text":"Includes 766 Stock Options granted by the Issuer to each of Julian C. Baker and Dr. Cheong on June 17, 2026, pursuant to the 2026 Plan. The Stock Options have a strike price of $499.86, fully vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, subject to the applicable director's continuous service with the Issuer through such vesting date, and expire 10 years from the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Includes 766 Stock Options granted by the Issuer to each of Julian C. Baker and Dr. Cheong on June 17, 2026, pursuant to the 2026 Plan. The Stock Options have a strike price of $499.86, fully vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, subject to the applicable director's continuous service with the Issuer through such vesting date, and expire 10 years from the date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The acquisitions of the RSUs and Stock Options reported on this form represent grants to each of Julian C. Baker and Dr. Cheong of 454 RSUs on Table I and 766 Stock Options on Table II. These grants, totaling 908 RSUs and 1,532 Stock Options for Julian C. Baker and Dr. Cheong in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":1532,"derivative":{"exercise_price":499.86,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":1532},"source":{"system":"sec-edgar","filing":"0001193125-26-275800","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526275800/ownership.xml","form_type":"4"}},{"id":732669,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2026-06-18T20:03:45.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":1532,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F10","text":"Includes 766 Stock Options granted by the Issuer to each of Julian C. Baker and Dr. Cheong on June 17, 2026, pursuant to the 2026 Plan. The Stock Options have a strike price of $499.86, fully vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, subject to the applicable director's continuous service with the Issuer through such vesting date, and expire 10 years from the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Includes 766 Stock Options granted by the Issuer to each of Julian C. Baker and Dr. Cheong on June 17, 2026, pursuant to the 2026 Plan. The Stock Options have a strike price of $499.86, fully vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, subject to the applicable director's continuous service with the Issuer through such vesting date, and expire 10 years from the date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock (\"Stock Options\") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The acquisitions of the RSUs and Stock Options reported on this form represent grants to each of Julian C. Baker and Dr. Cheong of 454 RSUs on Table I and 766 Stock Options on Table II. These grants, totaling 908 RSUs and 1,532 Stock Options for Julian C. Baker and Dr. Cheong in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":1532,"derivative":{"exercise_price":499.86,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":1532},"source":{"system":"sec-edgar","filing":"0001193125-26-275800","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526275800/ownership.xml","form_type":"4"}}],"next_cursor":"2026-06-18T20:03:45.000000Z,732669"}